bluebird bio, Inc. (NASDAQ:BLUE) Expected to Post Q4 2025 Earnings of ($0.04) Per Share

bluebird bio, Inc. (NASDAQ:BLUE) – Equities researchers at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for shares of bluebird bio in a research report issued on Tuesday, September 24th. Leerink Partnrs analyst M. Foroohar anticipates that the biotechnology company will earn ($0.04) per share for the quarter. The consensus estimate for bluebird bio’s current full-year earnings is ($1.57) per share.

A number of other research firms have also recently commented on BLUE. Barclays decreased their price target on bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a research note on Thursday, August 15th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price target on shares of bluebird bio in a research note on Thursday, August 15th. Cantor Fitzgerald reiterated a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. StockNews.com started coverage on bluebird bio in a research note on Friday. They issued a “sell” rating for the company. Finally, Robert W. Baird decreased their price target on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $4.63.

bluebird bio Trading Up 1.4 %

bluebird bio stock opened at $0.50 on Thursday. The stock has a 50-day moving average of $0.77 and a two-hundred day moving average of $0.97. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.82 and a current ratio of 0.93. bluebird bio has a one year low of $0.46 and a one year high of $5.53. The stock has a market cap of $55.15 million, a PE ratio of -0.68 and a beta of 0.75.

Institutional Trading of bluebird bio

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Masters Capital Management LLC acquired a new stake in bluebird bio during the fourth quarter worth about $1,380,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in bluebird bio by 38.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock worth $416,000 after acquiring an additional 90,139 shares during the period. Virtu Financial LLC acquired a new stake in bluebird bio during the fourth quarter worth about $317,000. HBK Investments L P acquired a new stake in bluebird bio during the fourth quarter worth about $2,070,000. Finally, Vestal Point Capital LP acquired a new stake in bluebird bio during the fourth quarter worth about $2,967,000. 87.43% of the stock is owned by institutional investors and hedge funds.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.